These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24288174)

  • 1. Risk of venous thrombosis varies with different types of combined oral contraceptives.
    DeSancho MT
    Evid Based Med; 2014 Apr; 19(2):e11. PubMed ID: 24288174
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Review: Combined oral contraceptives are associated with venous thrombosis.
    Harper DM; Wilfling LE; Blanner CF
    Ann Intern Med; 2013 Dec; 159(12):JC12. PubMed ID: 24343405
    [No Abstract]   [Full Text] [Related]  

  • 3. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
    Stegeman BH; de Bastos M; Rosendaal FR; van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
    BMJ; 2013 Sep; 347():f5298. PubMed ID: 24030561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women.
    Stegeman BH; Raps M; Helmerhorst FM; Vos HL; van Vliet HA; Rosendaal FR; van Hylckama Vlieg A
    J Thromb Haemost; 2013 Jan; 11(1):203-5. PubMed ID: 23122048
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation.
    Spitzer WO
    J Obstet Gynaecol Can; 2004 Jun; 26(6):549-50. PubMed ID: 15762006
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral contraceptives and venous thromboembolic events.
    Shulman LP; Goldzieher JW; Minkin MJ; Sulak PJ; Thorneycroft I
    J Reprod Med; 2003 Apr; 48(4):306-7. PubMed ID: 12747000
    [No Abstract]   [Full Text] [Related]  

  • 7. [Oral contraceptives: 30 vs 20 micrograms of ethinyl estradiol (EE)].
    Urdinola J
    Adv Contracept; 1994 Jul; 10 Suppl 1():41-9. PubMed ID: 7839871
    [No Abstract]   [Full Text] [Related]  

  • 8. Low dose contraceptive formulations: is further reduction in steroid dosage justified?
    Elstein M
    Adv Contracept; 1994 Mar; 10(1):1-4. PubMed ID: 8030448
    [No Abstract]   [Full Text] [Related]  

  • 9. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
    Cremer P; Vekemans M
    Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
    [No Abstract]   [Full Text] [Related]  

  • 10. Oral contraceptives according to the normophasic principle.
    Borglin NE; Klottrup P
    Arzneimittelforschung; 1978; 28(12):2354-7. PubMed ID: 582954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Misleading advertising.
    Bridge DT
    Med J Aust; 1987 Feb; 146(4):229-30. PubMed ID: 3574223
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clarification concerning NuvaRing].
    Jonsson M
    Lakartidningen; 2007 Jan 31-Feb 6; 104(5):355. PubMed ID: 17328363
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in alpha 1-antitrypsin (AAT) and alpha 2-macroglobulin serum concentrations during treatment with oral estro-progestogens.
    Paternoster D; Maggino T; Valente S; Pengo V; Ongaro G
    Quad Sclavo Diagn; 1982 Jun; 18(2):132-9. PubMed ID: 6188185
    [No Abstract]   [Full Text] [Related]  

  • 14. Renewed interest in haemostasis changes induced by oral contraceptives (OCs).
    Kluft C
    Thromb Haemost; 2000 Jul; 84(1):1-3. PubMed ID: 10928460
    [No Abstract]   [Full Text] [Related]  

  • 15. [Advances in hormonal contraception. A new micro-pll with especially low hormone effect].
    Gynakologe; 1994 Apr; 27(2 Suppl):1-12. PubMed ID: 9131064
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined hormonal contraception and the risk of venous thromboembolism: a guideline.
    ;
    Fertil Steril; 2017 Jan; 107(1):43-51. PubMed ID: 27793376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives.
    Alsina JC
    Eur J Contracept Reprod Health Care; 2010 Feb; 15(1):1-3. PubMed ID: 20136565
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    Raps M; Helmerhorst FM; Fleischer K; Dahm AE; Rosendaal FR; Rosing J; Reitsma P; Sandset PM; van Vliet HA
    Thromb Haemost; 2013 Apr; 109(4):606-13. PubMed ID: 23407778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone: high risk of venous thrombosis.
    Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis.
    Farris M; Bastianelli C; Rosato E; Brosens I; Benagiano G
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1129-1144. PubMed ID: 28712325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.